Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY24 results · Jul–Sep 2023
Procter & Gamble Health reported revenue from operations of ₹304.93 crore (up 2.5% from Q2 FY23) and net profit of ₹65.57 crore (up 3.0% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a standalone basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 304.93 | 297.55 | +2.5% | 301.18 | +1.2% |
| Other income | 6.05 | 3.42 | +76.9% | 5.46 | +10.8% |
| Total income | 310.98 | 300.97 | +3.3% | 306.64 | +1.4% |
| Profit before tax | 88.05 | 86.60 | +1.7% | 44.13 | +99.5% |
| Net profit for the period | 65.57 | 63.66 | +3.0% | 29.82 | +119.9% |
| EPS, basic (₹) | 39.50 | 38.30 | not comparable | 17.96 | +119.9% |
| Net margin (%) | 21.5 | 21.4 | 9.9 |
Standalone
- Filed with BSE
- 07 Nov 2023, 10:18 IST
- Board meeting
- 03 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE